Clinical trial
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in…
NCT00144170 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00144170 |
|---|---|
| Title | Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2) |
| Official title | Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Tipranavir (with low dose ritonavir), Comparator protease inhibitor(CPI)/low dose ritonavir(r) |
| Enrollment | 882 |
| Start date | Feb 1, 2003 |
| Primary completion | Oct 1, 2008 |
| First posted | Sep 5, 2005 |
| Last update posted | Jul 2, 2014 |
| Countries | Argentina, Austria, Belgium, Brazil, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: